Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Andrew Embleton-ThirskElizabeth DeaneStephen TownsendLaura FarrellyBabasola PopoolaJudith ParkerGordon RustinMatthew Robert SydesMahesh ParmarJonathan LedermannRichard KaplanPublished in: Clinical trials (London, England) (2019)
The conduct of this pragmatic, academic-sponsored trial was sufficient given the robustness of the results, shown by the results remaining largely unchanged following retrospective verification despite not being designed for use in a marketing authorization. The burden of such comprehensive retrospective effort required to ensure the results of ICON6 were acceptable to regulators is difficult to justify.